NSCLC

[Molecular Cancer therapeutics] Scientists selected five NSCLC patient-derived xenografts (PDXs) with genetic alterations from established PDXs and the corresponding molecular targeted therapy was administered orally for 21 consecutive days.

[Journal of Experimental & Clinical Cancer Research] The authors reported that stimuli from the embryonic lung could modulate the malignant phenotype of lung cancer cells, control their growth capacity and activate their differentiation into myofibroblasts.

[Scientific Reports] Researchers developed a lung adenocarcinoma (LUAD) hypoxia-related gene expression signature. RNAseq was used to identify genes significantly differentially expressed under hypoxia in four LUAD cell lines.

[Lyell Immunopharma, Inc.] Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.

[Cell Death Discovery] Investigators suggested that treatment with vascular endothelial growth factor receptor 2 (VEGFR2)-tyrosine kinase inhibitors upregulated ADRB2 expression in NSCLC cells.

[Cell Death & Disease] Scientists found that ERβ could promote NSCLC cell invasion via increasing the circular RNA (circRNA), circ-TMX4, expression via directly binding to the 5′ promoter region of its host gene TMX4.